The Kooyong Classic has welcomed tennis legend and former Wimbledon champion Pat Cash as an official ambassador for the ...

Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...

Sarepta Therapeutics (SRPT) stock is reeling this week following the death of a 16-year-old patient treated with its flagship gene therapy, ...

Kepler Capital analyst David Evans maintained a Buy rating on Novartis AG (NOVN – Research Report) on March 13 and set a price target of CHF106.00. The company’s shares closed yesterday at ...

TOKYO, March 17 (Reuters) - Swiss pharmaceutical giant Novartis (NOVN.S), opens new tab will watch "very carefully" how the reciprocal tariff policy proposed by the United States unfolds in early ...

For new and old investors, taking full advantage of the ... percentage change in earnings estimates. Switzerland-based Novartis has one of the strongest and broadest portfolios of varied drugs ...

ZURICH, Feb 25 (Reuters) - Emasan AG, an arm of the Sandoz Family Foundation, has launched a public offering of some 26.5 million shares in Swiss pharmaceutical firm Novartis to raise up to $3 ...

In the last year, some drugmakers have pulled back from the sector, including Pfizer, which recently stopped selling its gene ...

Swiss pharmaceutical company Novartis is staying put at its Midtown office right next to Bryant Park. “We worked closely with Novartis to secure a new lease extension that addressed the firm’s current ...

Novartis: 1996 – 2013 Dr Daniel Vasella was the first CEO of the newly merged company. Vasella was hired by Sandoz back in 1988 and remained there until 1992 when he was promoted to CEO of its ...

“Looks like a school project,” “Ampanget (Ugly),” and “The old logo was better” were among the comments on MIAA’s Facebook post about the logo reveal. MIAA said it was introducing a ...